Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGM
$3.14
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-24.0M · quality 40.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$808M
P/E
N/A
•EV/EBITDA
N/A
•ROE
7.5%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3.2%
FCF / Net income
0.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $403.1M · net income $-22.7M · FCF $-13.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $403.1M | $403.1M | $332.3M | $116.3M | $75.5M | $78.4M | $227.5M | $148.4M | $0.00 | — | — | — | — | — | — | — | — |
| Net Income | $-22.7M | $-22.7M | $-51.7M | $-209.2M | $-233.7M | $-269.1M | $-143.6M | $-97.2M | $-201.8M | $-167.0M | $-75.0M | $-49.8M | $-36.4M | $-26.1M | $-11.7M | $-10.8M | $-19.4M |
| EPS | -0.11 | -0.11 | -0.28 | -2.03 | -3.52 | -9.31 | -5.23 | -3.59 | — | — | — | — | — | — | — | — | — |
| Operating Margin | 15.0% | 15.0% | 16.4% | -133.7% | -237.8% | -289.0% | -53.3% | -62.8% | — | — | — | — | — | — | — | — | — |
| Net Margin | -5.6% | -5.6% | -15.6% | -179.9% | -309.6% | -343.0% | -63.1% | -65.5% | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.01 | 0.03 | — | -0.18 | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-13.1M | $-13.1M | $-24.0M | $-135.5M | $-174.8M | $-263.8M | $-86.0M | $-71.3M | $-148.8M | $-131.3M | $-47.8M | $-38.5M | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | 7.5% | 7.5% | 13.3% | 46.0% | 72.2% | 136.6% | 149.3% | -487.0% | -255.1% | -68.2% | -32.8% | -17.3% | -27.2% | -35.2% | 28.4% | 36.0% | 100.5% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 21.3% | 21.3% | 185.7% | 54.1% | -3.8% | -65.5% | 53.4% | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 60.7% | 60.7% | 86.2% | 42.3% | 62.2% | -78.0% | -45.7% | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.